TISSIUM
74, Rue du Faubourg Saint-Antoine
Paris
75012
France
Tel: 33-1-76-21-72-28
Website: http://www.tissium.com/
39 articles with TISSIUM
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Appoints Ruth Krestin as Vice President of Portfolio Strategy
1/10/2022
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has appointed Ruth Krestin as Vice President of Portfolio Strategy within TISSIUM.
-
TISSIUM to Present Study Results at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress
10/6/2021
TISSIUM will present an e-poster on its research on a novel, atraumatic, and consistent hernia mesh fixation device at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress. The event is scheduled to be held virtually and in-person from October 13 – October 16, 2021 in Copenhagen, Denmark.
-
TISSIUM to Present Study Results at the 76th Annual Meeting of the American Society for Surgery of the Hand
9/24/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage
8/31/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors.
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Appoints Romain Attard as Chief Financial Officer
7/1/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced Romain Attard has been appointed Chief Financial Officer of TISSIUM.
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
TISSIUM Selected for French Tech 120 Program
2/9/2021
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been named a French Tech 120 company for the 2021 program.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
BioSpace Movers & Shakers, Dec. 18
12/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
11/17/2020
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to de
-
TISSIUM Secures €7M State Guaranteed Loan
10/1/2020
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has secured a €7M state-guaranteed loan ( Prêt Garanti par l’Etat , or PGE). The loan was awarded by BNP Paribas, CM-CIC and bpifrance. Initiated by the French Government to support companies during the COVID-19 crisis, the PGE is a bank loan with a fixed interest rate ranging from 0.25% and 1.
-
TISSIUM Receives CE Mark and Announces Manufacturing Compliance Certification from TÜV SÜD
4/2/2020
TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced the receipt of a CE-mark for its sterile biodegradable sealant in a pre-filled syringe.
-
BioSpace Global Roundup, March 5
3/5/2020
Life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, Feb. 13
2/13/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
TISSIUM Receives Funding From the Crohn's & Colitis Foundation to Improve IBD Patient Outcomes
2/11/2020
Feb. 11, 2020 13:00 UTC PARIS--( BUSINESS WIRE )-- TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today that they have received funding from the Crohn's & Colitis Foundation's IBD Ventures, a funding mechanism intended to accelerate the discovery and development of novel research-based products with the potential to alleviate suffering caused by inflammatory bowel disease (IBD). The funding will support T
-
BioSpace Global Roundup, Jan. 23
1/23/2020
Companies from across the globe provide updates on their businesses and pipelines.